BCL2 and B-cell chronic lymphocytic leukemia: Expression of BTK, Bcl-2, CD20, and CD19 targets in diseased CLL and normal B cells leads to indiscriminate elimination of normal B cells leading to compromised B cell functions in patients that respond to therapy.